Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Gilead Sciences is the first and so far only company ... He also suggested there might be some shortcomings in the design, for example a lack of confirmation of COVID-19 infection at enrolment ...

ObvioHealth, a global leader in digital clinical trial solutions, announces the appointment of Richard Watkins as Chief Revenue Officer (CRO). With over 20 years of experience in sales leadership, ...

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced ...

Element Biosciences, Inc., a developer of pioneering technologies to empower science, today introduced Trinitytm - an innovative solution that simplifies target capture sequencing by eliminating or ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%.